PD-L1 Biomolecules Associated with Clinical Features in Non-Melanoma Skin Cancer
暂无分享,去创建一个
[1] M. Lacouture,et al. CME Part I: Immune checkpoint inhibitors to treat cutaneous malignancies. , 2020, Journal of the American Academy of Dermatology.
[2] A. Lokki,et al. Eculizumab Treatment for Postpartum HELLP Syndrome and aHUS—Case Report , 2020, Frontiers in Immunology.
[3] E. Gagari,et al. Advanced cutaneous squamous cell carcinoma: how is it defined and what new therapeutic approaches are available? , 2019, Current opinion in oncology.
[4] E. Hui. Immune checkpoint inhibitors , 2019, Reactions Weekly.
[5] M. Zhou,et al. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape , 2019, Molecular Cancer.
[6] A. Wrona. Role of immunotherapy in stage III nonsmall cell lung cancer , 2019, Current opinion in oncology.
[7] Haibo Yu,et al. Indoleamine 2, 3-dioxygenase and B7-H1 expressions as prognostic and follow-up markers in human pancreatic carcinoma. , 2018, Pathology, research and practice.
[8] A. Hauschild,et al. PD‐1 Blockade with Cemiplimab in Advanced Cutaneous Squamous‐Cell Carcinoma , 2018, The New England journal of medicine.
[9] Q. Du,et al. B7‐H3 expression and its correlation with clinicopathologic features, angiogenesis, and prognosis in intrahepatic cholangiocarcinoma , 2018, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[10] S. Paydaş,et al. PD-1 and PD-L1 expression in thymic epithelial tumours and non-neoplastic thymus , 2018, Journal of Clinical Pathology.
[11] C. Schmults,et al. Cutaneous squamous cell carcinoma: Incidence, risk factors, diagnosis, and staging. , 2018, Journal of the American Academy of Dermatology.
[12] J. Dai,et al. Association between B7-H1 and cervical cancer: B7-H1 impairs the immune response in human cervical cancer cells , 2017, Experimental and therapeutic medicine.
[13] A. Iyer,et al. PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome , 2017, Front. Pharmacol..
[14] G. Pupo,et al. PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors , 2017, Clinical Cancer Research.
[15] M. Mohammadi,et al. RETRACTED ARTICLE: Prognostic investigations of B7-H1 and B7-H4 expression levels as independent predictor markers of renal cell carcinoma , 2015, Tumor Biology.
[16] E. Wherry,et al. Molecular and cellular insights into T cell exhaustion , 2015, Nature Reviews Immunology.
[17] Jingting Jiang,et al. Expression of costimulatory molecules B7-H1, B7-H4 and Foxp3+ Tregs in gastric cancer and its clinical significance , 2015, International Journal of Clinical Oncology.
[18] Rui Zhang,et al. B7-H1 and B7-H4 expression in colorectal carcinoma: correlation with tumor FOXP3(+) regulatory T-cell infiltration. , 2014, Acta histochemica.
[19] G. Esendagli,et al. T helper responses are maintained by basal-like breast cancer cells and confer to immune modulation via upregulation of PD-1 ligands , 2014, Breast Cancer Research and Treatment.
[20] Alison P. Klein,et al. Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape , 2012, Science Translational Medicine.
[21] H. V. van Boven,et al. Overall survival and PD‐L1 expression in metastasized malignant melanoma , 2011, Cancer.
[22] M. Caligiuri,et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. , 2010, Blood.
[23] Israel Lowy,et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Xiaomei Wang,et al. B7-H1 is correlated with malignancy-grade gliomas but is not expressed exclusively on tumor stem-like cells. , 2009, Neuro-oncology.
[25] J. Schlesselman,et al. Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] J. Allison,et al. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1 , 2003, Nature Immunology.
[27] T. Curiel,et al. Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity , 2003, Nature Medicine.
[28] G. Freeman,et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation , 2001, Nature Immunology.
[29] S. Dzik. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin 10 secretion , 2000 .
[30] G. Zhu,et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion , 1999, Nature Medicine.